Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 7/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | PTPRC | P08575 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14269128 | 1.00 | STAT3 (0.43) | STAT3CA2CA1MCL1ALDH1A1 | |
| SCHEMBL14269123 | 0.96 | STAT3 (0.42) | STAT3CA2CA1MCL1ALDH1A1 | |
| SCHEMBL4839122 | 0.96 | STAT3 (0.42) | STAT3CA2CA1MCL1ALDH1A1 | |
| SCHEMBL14269127 | 0.88 | STAT3 (0.39) | STAT3ALDH1A1CES1PTPRCTP53 | |
| SCHEMBL14269122 | 0.84 | STAT3 (0.39) | STAT3CES1TP53 | |
| SCHEMBL4915977 | 0.78 | CES1 (0.47) | ALDH1A1CES1PTPRCGAA | |
| SCHEMBL14269133 | 0.76 | OPRD1 (0.49) | ALDH1A1CES1PTPRCGAA | |
| SCHEMBL14269126 | 0.75 | STAT3 (0.36) | STAT3ALDH1A1PTPRC | |
| SCHEMBL14269120 | 0.75 | STAT3 (0.45) | STAT3ALDH1A1 | |
| SCHEMBL5746932 | 0.74 | CES1 (0.46) | ALDH1A1CES1PTPRCGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7332615-B2 | Hydrophilic analogs of 4,8-dihydrobenzodithiophene-4,8-diones as anticancer agents | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2008-02-19 | — | — | US | disclosed |
| US-20060069041-A1 | Novel hydrophilic analogs of 4,8-dihydrobenzodithiophene-4,8-diones as anticancer agents | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069041-A1 | Novel hydrophilic analogs of 4,8-dihydrobenzodithiophene-4,8-diones as anticancer agents | ABCG2, ABCC8, ABCB1 | STAT3 2030/4885CA2 3750/4885CA1 4035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.